Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

$34.42 -0.11 (-0.32%)

(As of 03:03 PM ET)

Apellis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
8

Buy
12

Based on 20 Wall Street analysts who have issued ratings for Apellis Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 8 have given a hold rating, 10 have given a buy rating, and 2 have given a strong buy rating for APLS.

Consensus Price Target

$49.94
45.10% Upside

According to the 20 analysts' twelve-month price targets for Apellis Pharmaceuticals, the average price target is $49.94. The highest price target for APLS is $106.00, while the lowest price target for APLS is $25.00. The average price target represents a forecasted upside of 45.10% from the current price of $34.42.

Get the Latest News and Ratings for APLS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Apellis Pharmaceuticals and its competitors.

APLS Analyst Ratings Over Time

Type	Current Forecast 12/19/23 to 12/18/24	1 Month Ago 11/19/23 to 11/18/24	3 Months Ago 9/20/23 to 9/19/24	1 Year Ago 12/19/22 to 12/19/23
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	10 Buy rating(s)	11 Buy rating(s)	10 Buy rating(s)	10 Buy rating(s)
Hold	8 Hold rating(s)	6 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$49.94	$51.06	$71.67	$65.07
Forecasted Upside	45.10% Upside	95.03% Upside	95.12% Upside	12.23% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Healthcare Takes A Big Step Forward With The Help of A.I. (Ad)

To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.

Click here to learn more about the booming eHealth industry - and see which microcap will be at the

APLS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

APLS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Apellis Pharmaceuticals Stock vs. The Competition

Type	Apellis Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.70	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	41.33% Upside	28,482.21% Upside	11.90% Upside
News Sentiment Rating	Positive News See Recent APLS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/17/2024	The Goldman Sachs Group 2 of 5 stars	S. Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$36.00	+6.95%
11/21/2024	Morgan Stanley 3 of 5 stars		Initiated Coverage	Equal Weight	$31.00	+12.77%
11/7/2024	Robert W. Baird 2 of 5 stars		Lower Target	Outperform ➝ Outperform	$92.00 ➝ $55.00	+91.37%
11/6/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$63.00 ➝ $51.00	+80.98%
11/6/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sector Perform ➝ Sector Perform	$35.00 ➝ $30.00	+3.02%
11/6/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$43.00 ➝ $30.00	+6.08%
Healthcare Takes A Big Step Forward With The Help of A.I. (Ad) To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare. Click here to learn more about the booming eHealth industry - and see which microcap will be at the
11/6/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Amin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$40.00 ➝ $32.00	+13.98%
11/6/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$65.00 ➝ $40.00	+42.48%
11/6/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$85.00 ➝ $60.00	+113.71%
11/6/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$61.00 ➝ $47.00	+67.41%
11/6/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$83.00 ➝ $57.00	+103.03%
11/4/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Walter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$25.00 ➝ $25.00	-12.95%
10/31/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
10/24/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$39.00 ➝ $38.00	+40.85%
10/16/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Hanbury-Brown Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
9/13/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$64.00 ➝ $57.00	+52.00%
8/9/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$85.00 ➝ $83.00	+119.34%
8/9/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$38.00 ➝ $41.00	+8.72%
7/31/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00	+100.20%
1/11/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Strong-Buy ➝ Strong-Buy	$67.00 ➝ $106.00	+60.85%
8/29/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$60.00 ➝ $65.00	+63.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:22 PM ET.

APLS Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Apellis Pharmaceuticals is $49.94, with a high forecast of $106.00 and a low forecast of $25.00.
: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 8 hold ratings, 10 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APLS shares.
: According to analysts, Apellis Pharmaceuticals's stock has a predicted upside of 45.10% based on their 12-month stock forecasts.
: Over the previous 90 days, Apellis Pharmaceuticals's stock had 1 upgrade and 1 downgrade by analysts.
: Apellis Pharmaceuticals has been rated by research analysts at Bank of America, Citigroup, Evercore ISI, HC Wainwright, Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Scotiabank, The Goldman Sachs Group, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Apellis Pharmaceuticals less than other "medical" companies. The consensus rating score for Apellis Pharmaceuticals is 2.70 while the average consensus rating score for "medical" companies is 2.81. Learn more on how APLS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

This page (NASDAQ:APLS) was last updated on 12/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target